Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease